AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$HNGE

Perez Daniel Antonio sold $8.9M of HNGE

Perez Daniel Antonio (CEO & Co-Founder) sold 100,000 shares of Hinge Health, Inc. (HNGE) at an average of $89.45 ($88.22–$91.60, $8.94M total) across 5 trades on 2026-09-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Perez Daniel Antonio
Published Sep 11, 2026, 11:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 11:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$HNGE
Bearish
medium confidence
Mentioned
$HNGE
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HNGEBearishLow
01

Why it matters

The CEO's $8.9M share sale could be interpreted as a lack of confidence, but the pre‑arranged plan suggests routine execution.

02

Market read

The filing provides the first public disclosure of a sizable insider sell, offering traders a fresh data point.

03

What to watch

The sale was pre‑arranged under a 10b5‑1 plan, reducing the informational content.

Relevance 5/10Novelty 6/10Timing: post-market 2026-09-10

Background

Hinge Health is a digital therapeutics company listed on Nasdaq. Insider transactions are disclosed via Form 4.

Company-level read

Ticker impact

$HNGEBearishMedium confidence
Context

CEO Daniel Antonio sold 100,000 shares for $8.9M via a 10b5-1 plan, reducing his stake to 45,000 shares.

Expected impact

Possible modest downside pressure over the next few days.

Evidence & confidence

Large insider sale by the CEO, executed through a pre-arranged plan, often leads to market skepticism.

Market effects

Sector

Minimal impact on digital health sector; isolated insider activity.

Regional

Limited to US markets where HNGE trades.

Global

Low

Counterpoint

What could challenge this read

Insider sale may be routine liquidity management, not a negative signal.

Key entities

  • Insider
    Daniel Antonio Perez

    CEO & Co‑Founder of Hinge Health

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

HNGE insider trading history →

Related articles

$HNGEHighAI 8/10

Needham raises Hinge Health stock price target on client growth

Needham raised its price target for Hinge Health (NYSE:HNGE) to $135 from $115, citing strong client growth and quarterly performance. The company reported 28% year-over-year client growth, 50% revenue increase, and 154% stock return over six months. Q3 revenue was $235 million, up 52% year-over-year, with EPS of $0.66 beating estimates. Wells Fargo also raised its target to $132, noting strong margins and revenue growth.

investing.com
$HNGEHighAI 8/10

Hinge Health (HNGE) Q3 2026 Earnings Call Transcript

Hinge Health (HNGE) reported Q3 2026 revenue of $235M, up 52% YoY, with gross margin at 88% and operating income at $77M. The company highlighted growth in its MSK, Migraine, and GI care programs, with strong early results in Migraine care. President Jim Pursley announced his departure at year-end to spend more time with family but will join the board.

finance.yahoo.com